Changes of serum sPD-1 levels in HBeAg-positive chronic hepatitis B patients with entecavir treatment and correlation with curative effect

被引:10
|
作者
Bi, Chunhua [1 ]
Huang, Deyu [1 ]
Jiang, Jing [1 ]
Jiang, Yueping [2 ]
Wang, Hui [1 ]
Bian, Cheng [1 ]
Tian, Zibin [2 ]
机构
[1] Qingdao Univ, Affiliated Hosp, Dept Infect Dis, Qingdao, Shandong, Peoples R China
[2] Qingdao Univ, Affiliated Hosp, Dept Gastroenterol, Qingdao, Shandong, Peoples R China
关键词
sPD-1; chronic hepatitis B; entecavir; curative effect; CHRONIC VIRAL-INFECTION; T-CELLS; PROGRAMMED DEATH-1; ABERRANT REGULATION; VIRUS-INFECTION; SOLUBLE PD-1; IN-VIVO; IMMUNITY; HEPATOCARCINOMA; ACTIVATION;
D O I
10.3906/sag-1708-121
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background/aim: This study aimed to assess expression changes of serum sPD-1 levels in HBeAg-positive chronic hepatitis B patients with entecavir treatment and explore the correlation with the curative effect. Materials and methods: A total of 220 HBeAg-positive CHB patients and 207 healthy individuals were included. sPD-1 levels and virological and biochemical responses were assessed at baseline and at 12, 24, and 48 weeks in CHB patients after antiviral therapy. Results: sPD-1 levels in HBeAg-positive CHB patients before treatment were significantly lower than those of healthy controls. After entecavir treatment, sPD-1 levels increased gradually over time. At 48 weeks after entecavir treatment, sPD-1 amounts in the HBeAg seroconversion group were significantly higher than the values of the HBeAg-negative and HBeAg-positive groups. sPD-1 levels in patients with alanine aminotransferase (ALT) returning to normal were significantly higher than in those with ALT not returning to normal. sPD-1 levels in treated patients with no HBV-DNA were significantly higher than in those with HBV-DNA remaining positive. sPD-1 was negatively correlated with ALT and HBV-DNA at 12, 24, and 48 weeks after entecavir treatment. Conclusion: sPD-1 may play a certain role in chronic hepatitis B and has a close relationship with the curative effect of entecavir.
引用
收藏
页码:286 / 292
页数:7
相关论文
共 50 条
  • [1] A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B
    Chang, TT
    Gish, RG
    de Man, R
    Gadano, A
    Sollano, J
    Chao, YC
    Lok, AS
    Han, KH
    Goodman, Z
    Zhu, J
    Cross, A
    DeHertogh, D
    Wilber, R
    Colonno, R
    Apelian, D
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (10): : 1001 - 1010
  • [2] Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B
    Sherman, Morris
    Yurdaydin, Cihan
    Sollano, Jose
    Silva, Marcelo
    Liaw, Yun-Fan
    Cianciara, Janusz
    Boron-Kaczmarska, Anna
    Martin, Paul
    Goodman, Zachary
    Colonno, Richard
    Cross, Anne
    Denisky, Gail
    Kreter, Bruce
    Hindes, Robert
    GASTROENTEROLOGY, 2006, 130 (07) : 2039 - 2049
  • [4] Commentary: tenofovir is superior to entecavir in HBeAg-positive chronic hepatitis B patients
    Bradshaw, D.
    Danta, M.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 39 (09) : 992 - 992
  • [5] A one-year trial of entecavir treatment in patients with HBeAg-positive chronic hepatitis B
    Ren, Fen-Yu
    Piao, Dong-Ming
    Piao, Xi-Xu
    WORLD JOURNAL OF GASTROENTEROLOGY, 2007, 13 (31) : 4264 - 4267
  • [6] Association between KIR Genes and Efficacy of Treatment of HBeAg-Positive Chronic Hepatitis B Patients with Entecavir
    Zhuang, Yun-Long
    Li, Xi-Xi
    Xu, Hui-Cong
    Ye, Hui
    Sun, Di
    Liu, Xiang-Zhong
    Ren, Gui-Jie
    IRANIAN JOURNAL OF IMMUNOLOGY, 2018, 15 (02) : 112 - 121
  • [7] Entecavir therapy for up to 96 weeks in patients with HBeAg-Positive chronic hepatitis B
    Gish, Robert G.
    Lok, Anna S.
    Chang, Ting-Tsung
    De Man, Robert A.
    Gadano, Adrian
    Sollano, Jose
    Han, Kwang-Hyub
    Chao, You-Chen
    Lee, Shou-Dong
    Harris, Melissa
    Yang, Joanna
    Colonno, Richard
    Brett-Smith, Helena
    GASTROENTEROLOGY, 2007, 133 (05) : 1437 - 1444
  • [8] Prediction of response to entecavir therapy in patients with HBeAg-positive chronic hepatitis B based on on-treatment HBsAg, HBeAg and HBV DNA levels
    Shin, J. W.
    Jung, S. W.
    Park, B. R.
    Kim, C. J.
    Eum, J. B.
    Kim, B. G.
    Jeong, I. D.
    Bang, S. -J.
    Lee, S. -H.
    Kim, S. R.
    Park, N. H.
    JOURNAL OF VIRAL HEPATITIS, 2012, 19 (10) : 724 - 731
  • [9] ASSOCIATION BETWEEN GENOTYPE AND BASELINE HBsAg LEVELS AND THE HBsAg LEVELS AT HBeAg SEROCLEARANCE IN HBeAg-POSITIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH ENTECAVIR
    Peng, C. -Y.
    Lai, H. -C.
    Su, W. -P.
    Lin, C. -H.
    Chuang, P. -H.
    Chen, S. -H.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S430 - S430
  • [10] Addition of (pegylated) interferon to entecavir increases response in treatment naive HBeAg-positive patients with chronic hepatitis B
    Liem, S.
    van Campenhout, M. J.
    Chi, H.
    Brouwer, W. P.
    Xie, Q.
    Qi, X.
    Liang, C.
    Tabak, F.
    Hansen, B. E.
    Janssen, H. L.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S692 - S692